Dynamic contrast-enhanced and diffusion-weighted MR imaging in early prediction of pathologic response to neoadjuvant chemotherapy in locally advanced gastric cancer
- PMID: 35916943
- DOI: 10.1007/s00261-022-03623-0
Dynamic contrast-enhanced and diffusion-weighted MR imaging in early prediction of pathologic response to neoadjuvant chemotherapy in locally advanced gastric cancer
Abstract
Purpose: To investigate the efficacy of diffusion-weighted imaging (DWI) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) for the early prediction of the pathologic response to neoadjuvant chemotherapy (NAC) in patients with locally advanced gastric cancer (LAGC).
Methods: Fifty patients with LAGC who were treated with NAC followed by radical gastrectomy were enrolled. Uncontrasted and DCE-MRI were performed within 1 week before NAC. According to tumor regression grading (TRG), patients were labeled as responders (TRG = 0 + 1) and non-responders (TRG = 2 + 3). Apparent diffusion coefficients (ADC) and DCE-MRI kinetics (Ktrans, Ve, and Kep) were compared between the two groups. Logistic regression analysis was performed to screen independent factors to predict the NAC efficacy. The relationship between MRI parameters and TRG was studied by Spearman's correlation analysis. Receiver-operating characteristic curve analyses were applied to evaluate the efficacy.
Results: ADC, Ktrans, and Kep values were higher in responders than in non-responders (p < 0.05) and correlated with TRG (p < 0.05). The ADC and Kep values were independent markers for predicting TRG. The area under the curve, sensitivities, specificities of ADC, Ktrans, Kep, and ADC + Kep were 0.813, 0.699, 0.709, 0.886;73.64%, 65.54%, 63.21%, 70.37%; 86.47%, 54.97%, 79.47%, 95.65%; respectively. ADC + Kep demonstrated a higher efficacy than Ktrans and Kep (p = 0.012, 0.011), but without improvement compared with ADC (p > 0.05).
Conclusion: Both DWI and DCE-MRI can effectively predict the pathologic response to NAC in LAGC. A combination of ADC and Kep increased the efficacy, and ADC is the most valuable imaging parameter.
Keywords: Diffusion-weighted MR imaging; Dynamic contrast-enhanced MR imaging; Gastric cancer; Neoadjuvant chemotherapy; Treatment response.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Spectral CT vs. diffusion-weighted imaging for the quantitative prediction of pathologic response to neoadjuvant chemotherapy in locally advanced gastric cancer.Eur Radiol. 2024 Sep;34(9):6193-6204. doi: 10.1007/s00330-024-10642-6. Epub 2024 Feb 12. Eur Radiol. 2024. PMID: 38345605
-
Quantitative Dynamic-Enhanced MRI and Intravoxel Incoherent Motion Diffusion-Weighted Imaging for Prediction of the Pathological Response to Neoadjuvant Chemotherapy and the Prognosis in Locally Advanced Gastric Cancer.Front Oncol. 2022 Mar 29;12:841460. doi: 10.3389/fonc.2022.841460. eCollection 2022. Front Oncol. 2022. PMID: 35425711 Free PMC article.
-
Multiparametric magnetic resonance imaging for predicting pathological response after the first cycle of neoadjuvant chemotherapy in breast cancer.Invest Radiol. 2015 Apr;50(4):195-204. doi: 10.1097/RLI.0000000000000100. Invest Radiol. 2015. PMID: 25360603 Free PMC article.
-
Meta-Analysis of Quantitative Dynamic Contrast-Enhanced MRI for the Assessment of Neoadjuvant Chemotherapy in Breast Cancer.Am Surg. 2019 Jun 1;85(6):645-653. Am Surg. 2019. PMID: 31267907 Review.
-
The assessment of pathological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer patients with DCE-MRI and DWI: a systematic review and meta-analysis.Br J Radiol. 2023 Oct;96(1150):20230239. doi: 10.1259/bjr.20230239. Epub 2023 Sep 3. Br J Radiol. 2023. PMID: 37660472 Free PMC article.
Cited by
-
Spectral CT vs. diffusion-weighted imaging for the quantitative prediction of pathologic response to neoadjuvant chemotherapy in locally advanced gastric cancer.Eur Radiol. 2024 Sep;34(9):6193-6204. doi: 10.1007/s00330-024-10642-6. Epub 2024 Feb 12. Eur Radiol. 2024. PMID: 38345605
-
Prognostic value of diffusion-weighted imaging to cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for patients with gastric cancer and peritoneal metastases.BMC Cancer. 2025 Apr 5;25(1):616. doi: 10.1186/s12885-025-14008-z. BMC Cancer. 2025. PMID: 40188022 Free PMC article.
-
Sequential dual-energy CT for longitudinal assessment of pathologic response to neoadjuvant immuno-chemotherapy in locally advanced gastric cancer.Eur Radiol. 2025 Apr 25. doi: 10.1007/s00330-025-11601-5. Online ahead of print. Eur Radiol. 2025. PMID: 40278873
-
Construction and validation of the prognostic nomogram model for patients with diffuse-type gastric cancer based on the SEER database.Discov Oncol. 2024 Jul 24;15(1):305. doi: 10.1007/s12672-024-01180-0. Discov Oncol. 2024. PMID: 39048774 Free PMC article.
-
Imaging advances in efficacy assessment of gastric cancer neoadjuvant chemotherapy.Abdom Radiol (NY). 2023 Dec;48(12):3661-3676. doi: 10.1007/s00261-023-04046-1. Epub 2023 Oct 3. Abdom Radiol (NY). 2023. PMID: 37787962 Review.
References
-
- Sung H, Ferlay J, Siegel RL et al. (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/ https://doi.org/10.3322/caac.21660 . - DOI - PubMed
-
- Gao K, Wu J (2019) National trend of gastric cancer mortality in China (2003–2015): a population-based study. Cancer Commun (Lond) 39(1):24. https://doi.org/ https://doi.org/10.1186/s40880-019-0372-x . - DOI
-
- Miller KD, Nogueira L, Mariotto AB et al. (2019) Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin 69:363–385. https://doi.org/ https://doi.org/10.3322/caac.21565 . - DOI - PubMed
-
- Cunningham D, Allum WH, Stenning SP et al. (2016) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20. https://doi.org/ https://doi.org/10.1056/NEJMoa055531 . - DOI
-
- Maria C Russell (2016) Comparison of neoadjuvant versus a surgery first approach for gastric and esophagogastric cancer. J Surg Oncol 114(3):296–303. https://doi.org/ https://doi.org/10.1002/jso.24293 . - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical